Bloom Burton Weighs in on BioSyent Inc.’s Q3 2023 Earnings (CVE:RX)

BioSyent Inc. (CVE:RX) – Research analysts at Bloom Burton upped their Q3 2023 earnings estimates for shares of BioSyent in a research report issued on Wednesday, August 23rd. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of $0.10 per share for the quarter, up from their prior estimate of $0.09. The consensus estimate for BioSyent’s current full-year earnings is $0.43 per share. Bloom Burton also issued estimates for BioSyent’s FY2023 earnings at $0.21 EPS.

BioSyent (CVE:RX) last released its quarterly earnings data on Friday, May 26th. The company reported C$0.10 earnings per share for the quarter, missing the consensus estimate of C$0.13 by C($0.03). The company had revenue of C$6.48 million during the quarter, compared to the consensus estimate of C$7.60 million. BioSyent had a net margin of 18.43% and a return on equity of 15.42%.

BioSyent Stock Performance

Shares of RX stock opened at C$7.80 on Monday. The firm has a market capitalization of C$92.74 million, a PE ratio of 19.50 and a beta of 0.79. The firm has a fifty day simple moving average of C$7.51 and a two-hundred day simple moving average of C$7.48. The company has a current ratio of 9.02, a quick ratio of 6.91 and a debt-to-equity ratio of 4.05. BioSyent has a 12 month low of C$6.24 and a 12 month high of C$8.30.

BioSyent Company Profile

BioSyent Inc, a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water or mixing oral iron supplement; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia.